ネモト　ユウキ   Nemoto Yuuki   根本　侑樹    所属   医学部 医学科（東京女子医科大学病院）    職種   助手
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
掲載誌名	正式名：International urology and nephrology 略　 称：Int Urol Nephrol ISSNコード：03011623/15732584
掲載区分	国外
巻・号・頁	54(1),pp.47-54
著者・共著者	NEMOTO Yuki†, ISHIHARA Hiroki*, NAKAMURA Kazutaka, TACHIBANA Hidekazu, FUKUDA Hironori, YOSHIDA Kazuhiko, KOBAYASHI Hirohito, IIZUKA Junpei, SHIMMURA Hiroaki, HASHIMOTO Yasunobu, TANABE Kazunari, KONDO Tsunenori, TAKAGI Toshio
担当区分	筆頭著者
発行年月	2022/01
概要	PURPOSE:To clarify the efficacy and safety profile of immune checkpoint inhibitors (ICIs) for elderly patients with metastatic renal cell carcinoma (mRCC).METHODS:We retrospectively evaluated 149 mRCC patients treated with nivolumab monotherapy as subsequent therapy (n = 89) and nivolumab plus ipilimumab as first-line therapy (n = 60) at 5 affiliated institutions. The patients were divided according to age: > 70 (elderly) vs. ≤ 70 years (young). Efficacy was analyzed by comparing progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) between elderly and young patients. Safety was assessed by comparing the incidence rates of immune-related adverse events (irAEs).RESULTS:In the nivolumab monotherapy group, 34/89 patients (38%) were classified as elderly. There was no significant difference in PFS (p = 0.607), OS (p = 0.383), ORR (p = 0.0699), or DCR (p = 0.881) between elderly and young patients. In the nivolumab plus ipilimumab group, 20/60 patients (33%) were classified as elderly. There was no significant difference in PFS (p = 0.995), OS (p = 0.714), ORR (p = 0.763), or DCR (p = 1.000) between the two groups. The incidence rate of irAEs was not significantly different in the nivolumab (any grade: p = 0.121; grade ≥ 3: p = 0.542) or in the nivolumab plus ipilimumab (any grade: p = 0.666; grade ≥ 3: p = 0.576) group; a higher rate of gastrointestinal irAEs was observed in elderly than in young patients (any grade 15% vs. 3%).CONCLUSIONS:The efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab were comparable between elderly and young patients. Thus, chronological age alone should not be a contraindication in the use of ICIs for mRCC.
DOI	10.1007/s11255-021-03042-y
PMID	34704214